Clinical Trials Search Results Display: Title Description with: Locations Eligibility Full Trial Description Custom ? Hide Search Criteria Show Search Criteria Country: U.S.A.Trial Type: Prevention Results 1-25 of 121 for your search: Start Over Select All on Page Sort by: Phase of Trial Title Type of Trial Status of Trial Age Range Trial ID Show 10 25 50 100 200 Results per Page 1. Behavioral Counseling and Nicotine Replacement Therapy or Varenicline in Helping Smokers Quit Status: ActivePhase: Phase IVType: Behavioral study, Biomarker/Laboratory analysis, PreventionAge: 18 to 65Trial IDs: 2014-0207, NCI-2014-01485, NCT02162849 2. Varenicline and Nicotine Replacement Therapy for Initial Smoking Cessation and Treatment in Smokers Status: ActivePhase: Phase IVType: Behavioral study, PreventionAge: 18 to 65Trial IDs: 2014-0213, NCI-2015-00610, NCT02271919 3. Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers Status: ActivePhase: Phase IVType: Biomarker/Laboratory analysis, PreventionAge: 18 and overTrial IDs: STUDY00001602, NCI-2015-01331, AD-1310-08709, NCI-2015-00937, NCT02244918 4. Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients with Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Status: ActivePhase: Phase IIIType: Biomarker/Laboratory analysis, PreventionAge: 18 and overTrial IDs: GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303 5. Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer Status: ActivePhase: Phase IIIType: PreventionAge: 18 and overTrial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881 6. Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Status: ActivePhase: Phase IIIType: PreventionAge: 15 and overTrial IDs: GHRT01, NCI-2014-02097, NCT01479283 7. Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer Status: ActivePhase: Phase IIIType: Biomarker/Laboratory analysis, PreventionAge: 25 to 55Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046 8. Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions Status: ActivePhase: Phase IIIType: Biomarker/Laboratory analysis, Natural history/Epidemiology, PreventionAge: 35 and overTrial IDs: AMC-A01, NCI-2014-00636, NCT02135419 9. Varenicline for Adolescent Smoking Cessation Status: ActivePhase: Phase IIIType: Biomarker/Laboratory analysis, PreventionAge: 14 to 21Trial IDs: Pro00014398, NCI-2016-02034, NCT01509547 10. A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants Status: ActivePhase: Phase IIIType: PreventionAge: 18 and overTrial IDs: CR107047, NCI-2016-00410, 2015-001630-21, 39039039STM4001, NCT02555878 11. Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant Status: ActivePhase: Phase II, Phase IType: PreventionAge: 18 to 70Trial IDs: 15-C-0067, NCI-2015-00084, P131448, NCT02356159 12. Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients with Hematologic Malignancies Undergoing HSCT Status: ActivePhase: Phase II, Phase IType: Biomarker/Laboratory analysis, Prevention, TreatmentAge: 3 to 30Trial IDs: PEDSBMT295, NCI-2016-00387, NCT02728700 13. Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Status: ActivePhase: Phase II, Phase IType: PreventionAge: 18 to 70Trial IDs: PT-001, NCI-2016-00907, NCT02743351 14. Azacitidine and Cyclophosphamide after Donor Stem Cell Transplantation in Preventing GVHD in Patients with Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Advanced Myelodysplastic Syndrome Status: ActivePhase: Phase II, Phase IType: Prevention, TreatmentAge: 18 and overTrial IDs: 201604081, NCI-2016-00582, NCT02750254 15. Pacritinib, Sirolimus, and Tacrolimus in Preventing Graft Versus Host Disease in Patients with Blood Cancer Undergoing Donor Stem Cell Transplant Status: ActivePhase: Phase II, Phase IType: Prevention, Supportive careAge: 18 and overTrial IDs: MCC-18783, NCI-2017-00594, NCT02891603 16. Vandetanib in Preventing Head and Neck Cancer in Patients with Precancerous Head and Neck Lesions Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, PreventionAge: 18 and overTrial IDs: 11-0265, NCI-2011-01246, NCT01414426 17. Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, Natural history/Epidemiology, PreventionAge: 9 to 26Trial IDs: X141204010, NCI-2011-03654, 000508488, 113426, F141204009, XUAB14102, NCT01492582 18. Donor Atorvastatin Treatment in Preventing Severe Acute GVHD after Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients with Hematological Malignancies Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, PreventionAge: 0 to 75Trial IDs: 2546.00, NCI-2011-03828, NCT01527045 19. Breast-Conserving Surgery and Radiation Therapy in Treating Patients with Multiple Ipsilateral Breast Cancer Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, PreventionAge: 40 and overTrial IDs: Z11102, NCI-2012-00707, ACOSOG-Z11102, CDR0000728605, NCT01556243 20. Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Status: ActivePhase: Phase IIType: PreventionAge: 18 and overTrial IDs: 368255, NCI-2015-00026, 1137008 / 20130058, NCT01570036 21. Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, PreventionAge: 18 to 60Trial IDs: CPKC412AUS23, NCI-2013-02275, NCT01883362 22. Metformin Hydrochloride in Reducing Obesity-Associated Breast Cancer Risk Status: ActivePhase: Phase IIType: PreventionAge: 30 to 45Trial IDs: 1300000596, NCI-2015-01211, 1300000596A024, NCT02028221 23. Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL Status: ActivePhase: Phase IIType: PreventionAge: 18 and overTrial IDs: SPI-FOL-14-201, NCI-2015-00888, NCT02106650 24. Erlotinib Hydrochloride in Treating Patients with Bladder Cancer Undergoing Surgery Status: ActivePhase: Phase IIType: Biomarker/Laboratory analysis, PreventionAge: 18 and overTrial IDs: CO12336, NCI-2014-01320, HHSN261201200033I, N01-CN-2012-00033, UWI2013-01-02, NCT02169284 25. Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer Status: ActivePhase: Phase IIType: PreventionAge: 50 to 80Trial IDs: 13-000432, NCI-2014-01257, NCT02176902 Select All on Page 1 Start Over
